Immuneering
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
245 Main St PMB 2, Cambridge, Massachuse...Phone Number
(617) 500-8080Website
www.immuneering.comRevenue
$14.4 MillionStock Symbol
IMRXIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
2
About Immuneering
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneerings lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The companys development pipeline also includes several early-stage programs.Explore more
Immuneering Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immuneering your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Immuneering had a recent Job posting/layoffs
Earning: See what the market has to say on Immuneering recently announced quarterly report
Immuneering, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Immuneering has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Immuneering has new funding data
Congratulate Masked Content for being promoted to Masked Content at Immuneering
Check out if Immuneering is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Immuneering launches new products
Recommended Actions
Reach out to Masked Content who joined Immuneering as Masked Content
Find more new buyers
Compare Similar Companies to Immuneering
Compare insights from companies similar to Immuneering, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immuneering is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immuneering is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immuneering.
Immuneering financials insights
Gather financial insights about Immuneering, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$20M
2021
Series B
$62M
Share Placement
$112.5M
2025
Stock/Share Issuance
$25M
Immuneering Tech Stack
A closer look at the technologies used by Immuneering
See more technologies
Most Recent Scoops
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
Immuneering News & Media
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line PatientsImmuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business UpdatesPublication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors -Immuneering Corporation Announces Grants of Inducement Awards
Immuneering Corporation Announces Grants of Inducement Awards
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immuneering
Sign Up For FreeTo access detailed company insights
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneerings lead product candidate, IMM-1-... Read More
